Prolonged and Inducible Transgene Expression in the Liver Using Gutless Adenovirus: A Potential Therapy for Liver Cancer

Gastroenterology

Volumn 126, Issue 1 SUPPL. 1, 2004, Pages 278-289

  Wang, Lin ^a,d   Hernández Alcoceba, Rubén ^a   Shankar, Vijay ^b   Zabala, Maider ^a   Kochanek, Stefan ^b,c   Sangro, Bruno ^a   Kramer, M Gabriela ^a   Prieto, Jesus ^a   Qian, Cheng ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MIFEPRISTONE; RECOMBINANT ALPHA2A INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA TRANSCRIPTION; DRUG BLOOD LEVEL; EXPERIMENTAL INFECTION; GENE THERAPY; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CELL; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

EID: 0347991866     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2003.10.075     Document Type: Article

References (52)

1. Shetty K, Wu GY, Wu CH. Gene therapy of hepatic diseases: prospects for the new millennium. Gut 2000;46:136-139.
2. Ghosh SS, Takahashi M, Thummala NR, Parashar B, Chowdhury NR, Chowdhury JR. Liver-directed gene therapy: promises, problems and prospects at the turn of the century. J Hepatol 2000; 32(1 Suppl):238-252.
3. Qian C, Drozdzik M, Caselmann WH, Prieto J. The potential of gene therapy in the treatment of hepatocellular carcinoma. J Hepatol 2000;32:344-351.
4. Mohr L, Geissler M, Blum HE. Gene therapy for malignant liver disease. Expert Opin Biol Ther 2002;2:163-175.
5. Schmitz V, Qian C, Ruiz J, Sangro B, Melero I, Mazzolini G, Narvaiza I, Prieto J. Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis. Gut 2002;50:130-135.
6. Sangro B, Qian C, Schmitz V, Prieto J. Gene therapy of hepatocellular carcinoma and gastrointerstinal tumors. Ann N Y Acad Sci 2002;963:6-12.
7. Ferry N, Heard JM. Liver-directed gene transfer vectors. Hum Gene Ther 1998;9:1975-1981.
8. Galimi F, Verma IM. Opportunities for the use of lentiviral vectors in human gene therapy. Curr Top Microbiol Immunol 2002;261: 245-254.
9. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001;7:33-40.
10. Graham FL. Adenovirus vectors for high-efficiency gene transfer into mammalian cells. Immunol Today 2000;21:426-428.
11. Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999;10:440-447.
12. Wilson JM. Adenovirus-mediated gene transfer to liver. Adv Drug Deliv Rev 2001;46:205-209.
13. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996;3:137-144.
14. Kochanek S. High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum Gene Ther 1999;10:2451-2459.
15. Morsy MA, Caskey CT. Expanded-capacity adenoviral vectors-the helper-dependent vectors. Mol Med Today 1999;5:18-24.
16. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996;93:13565-13570.
17. Morral N, Parks RJ, Zhou H, Langston C, Schiedner G, Quinones J, Graham FL, Kochanek S, Beaudet AL. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther 1998; 9:2709-2716.
18. Morral N, O'Neal W, Rice K, Leland M, Kaplan J, Piedra PA, Zhou H, Parks RJ, Velji R, Aguilar-Cordova E, Wadsworth S, Graham FL, Kochanek S, Carey KD, Beaudet AL. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci U S A 1999;96:12816-12821.
19. Morsy MA, Gu M, Motzel S, Zhao J, Lin J, Su Q, Allen H, Franlin L, Parks RJ, Graham FL, Kochanek S, Bett AJ, Caskey CT. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A 1998;95:7866-7871.
20. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A 2001;98: 13282-13287.
21. Chuah MK, Schiedner G, Thorrez L, Brown B, Johnston M, Gillijns V, Hertel S, Van Rooijen N, Lillicrap D, Collen D, Vanden-Driessche T, Kochanek S. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 2003; 101:1734-1743.
22. Balague C, Zhou J, Dai Y, Alemany R, Josephs SF, Andreason G, Hariharan M, Sethi E, Prokopenko E, Jan HY, Lou YC, Hubert-Leslie D, Ruiz L, Zhang WW. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 2000;95:820-828.
23. Reddy PS, Sakhuja K, Ganesh S, Yang L, Kayda D, Brann T, Pattison S, Golightly D, Idamakanti N, Pinkstaff A, Kaloss M, Barjot C, Chamberlain JS, Kaleko M, Connelly S. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol Ther 2002;5:63-73.
24. Ehrhardt A, Kay MA. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 2002;99:3923-3930.
25. Ruiz J, Mazzolini G, Sangro B, Qian C, Prieto J. Gene therapy of hepatocellular carcinoma. Dig Dis 2001;19:324-332.
26. Sung MW, Yeh HC, Thung SN, Schwartz ME, Mandeli JP, Chen SH, Woo SL. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther 2001;4:182-191.
27. Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SL, Chen SH. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci U S A 1996;93:11302-11306.
28. Mazzolini G, Qian C, Xie X, Sun Y, Lasarte J, Drozdzik M, Prieto J. Tumor regression and long-term protection for colon cancer after intratumoral injection of adenovirus expressing IL-12. Cancer Gene Ther 1999;5:514-522.
29. Barajas M, Mazzolini G, Genové G, Bilbao R, Narvaiza I, Schmitz V, Sangro B, Melero I, Qian C, Prieto J. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 2001;33:52-61.
30. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil J, Olage C, Sola J, Sadaba B, Lacasa C, Melero I, Qian C, Prieto J. A phase I clinical trial of intratumoral injection of an adenovirus encoding interleukin 12 for advanced digestive tumors. J Clin Oncol 2004; (In press).
31. Hendrzak JA, Brunda MJ. Interleukin 12: biological activity, therapeutic utility, and role in disease. Lab Invest 1995;72:619-637.
32. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998;70:83-243.
33. Orange JS, Salazar-Mather TP, Opal SM, Spencer RL, Miller AH, McEwen BS, Biron CA. Mechanisms of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J Exp Med 1995;181:901-914.
34. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997;90:2541-2548.
35. Harvey DM, Caskey CT. Inducible control of gene expression: prospects for gene therapy. Curr Opin Chem Biol 1998;2:512-518.
36. Rossi FM, Blau HM. Recent advances in inducible gene expression systems. Curr Opin Biotechnol 1998;9:451-456.
37. Miller N, Whelan J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum Gene Ther 1997;8: 803-815.
38. Clackson T. Regulated gene expression systems. Gene Ther 2000;7:120-125.
39. Agha-Mohammadi S, Lotze MT. Regulatable systems: applications in gene therapy and replicating viruses. J Clin Invest 2000; 105:1177-1183.
40. Ye X, Schillinger K, Burcin MM, Tsai SY, O'Malley BW. Ligand-inducible transgene regulation for gene therapy. Methods Enzymol 2002;346:551-561.
41. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995;268:1766-1769.
42. Rossi FM, Guicherit OM, Spicher A, Kringstein AM, Fatyol K, Blakely BT, Blau HM. Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16. Nat Genet 1998;20:389-393.
43. Hoppe UC, Marban E, Johns DC. Adenovirus-mediated inducible gene expression in vivo by a hybrid ecdysone receptor. Mol Ther 2000;1:159-164.
44. Ye X, Rivera VM, Zoltick P, Cerasoli F Jr, Schnell MA, Gao G, Hughes JV, Gilman M, Wilson JM. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999;283:88-91.
45. Wang Y, O'Malley BW Jr, Tsai SY, O'Malley BW. A regulatory system for use in gene transfer. Proc Natl Acad Sci U S A 1994;91:8180-8184.
46. Burcin MM, Schiedner G, Kochanek S, Tsai SY, O'Malley BW. Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci U S A 1999;96:355-360.
47. Wang Y, DeMayo FJ, Tsai SY, O'Malley BW. Ligand-inducible and liver-specific target gene expression in transgenic mice. Nat Biotechnol 1997;15:239-243.
48. Wang XJ, Liefer KM, Tsai S, O'Malley BW, Roop DR. Development of gene-switch transgenic mice that inducibly express transforming growth factor beta1 in the epidermis. Proc Natl Acad Sci U S A 1999;96:8483-8488.
49. Abruzzese RV, Godin D, Burcin M, Mehta V, French M, Li Y, O'Malley BW, Nordstrom JL. Ligand-dependent regulation of plasmid-based transgene expression in vivo. Hum Gene Ther 1999; 10:1499-1507.
50. Abruzzese RV, Godin D, Mehta V, Perrard JL, French M, Nelson W, Howell G, Coleman M, O'Malley BW, Nordstrom JL. Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible Gene-Switch system. Mol Ther 2000;2:276-287.
51. Kreppel F, Biermann V, Kochanek S, Schiedner G. A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations. Hum Gene Ther 2002;13:1151-1156.
52. Pastore L, Morral N, Zhou H, Garcia R, Parks RJ, Kochanek S, Graham FL, Lee B, Beaudet AL. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999;10:1773-1781.